Donald W Black1, Martha Shaw, Kelsie T Forbush, Jeff Allen. 1. Department of Psychiatry, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA 52242, USA. donald-black@uiowa.edu
Abstract
BACKGROUND: The effectiveness and tolerability of escitalopram was tested in the treatment of pathological gambling (PG). METHOD: Nondepressed outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition PG received flexibly dosed escitalopram in a prospective, 10-week, open-label trial after a 2-week observation period. Subjects were evaluated at baseline and at 2-week intervals for assessment of gambling behavior, mood symptoms, and adverse experiences. The primary efficacy measure was the Yale-Brown Obsessive-Compulsive Scale modified for PG. Secondary efficacy measures included the Clinical Global Impression (CGI) Improvement and Severity Scales, a patient self-rated global rating, the Sheehan Disability Scale, and the Timeline Follow Back. RESULTS: Nineteen subjects (12 men and 7 women) had at least 1 postbaseline visit and were included in the analysis; 16 subjects (84%) completed the protocol. Significant improvement was found in all measures, including the Yale-Brown Obsessive-Compulsive Scale modified for PG, both CGI Scales, a patient self-rated global scale, the Timeline Follow Back, the Attention-Deficit/Hyperactivity Disorder Checklist, the Hamilton Depression Rating Scale, and all 3 Sheehan Disability Scale subscales. Fourteen subjects (73.7%) were considered responders (ie, achieved "much" or "very much" improvement on the CGI). Few adverse experiences were reported. CONCLUSION: The results suggest that escitalopram is well tolerated and may be effective in the treatment of PG.
BACKGROUND: The effectiveness and tolerability of escitalopram was tested in the treatment of pathological gambling (PG). METHOD: Nondepressed outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition PG received flexibly dosed escitalopram in a prospective, 10-week, open-label trial after a 2-week observation period. Subjects were evaluated at baseline and at 2-week intervals for assessment of gambling behavior, mood symptoms, and adverse experiences. The primary efficacy measure was the Yale-Brown Obsessive-Compulsive Scale modified for PG. Secondary efficacy measures included the Clinical Global Impression (CGI) Improvement and Severity Scales, a patient self-rated global rating, the Sheehan Disability Scale, and the Timeline Follow Back. RESULTS: Nineteen subjects (12 men and 7 women) had at least 1 postbaseline visit and were included in the analysis; 16 subjects (84%) completed the protocol. Significant improvement was found in all measures, including the Yale-Brown Obsessive-Compulsive Scale modified for PG, both CGI Scales, a patient self-rated global scale, the Timeline Follow Back, the Attention-Deficit/Hyperactivity Disorder Checklist, the Hamilton Depression Rating Scale, and all 3 Sheehan Disability Scale subscales. Fourteen subjects (73.7%) were considered responders (ie, achieved "much" or "very much" improvement on the CGI). Few adverse experiences were reported. CONCLUSION: The results suggest that escitalopram is well tolerated and may be effective in the treatment of PG.
Authors: Donald Wayne Black; Martha Shaw; Brett McCormick; John David Bayless; Jeff Allen Journal: Psychiatry Res Date: 2012-07-04 Impact factor: 3.222
Authors: Donald W Black; Martha Shaw; William Coryell; Raymond Crowe; Brett McCormick; Jeff Allen Journal: Compr Psychiatry Date: 2015-04-20 Impact factor: 3.735
Authors: Matteo Lupi; Giovanni Martinotti; Tiziano Acciavatti; Mauro Pettorruso; Marcella Brunetti; Rita Santacroce; Eduardo Cinosi; Giuseppe Di Iorio; Marco Di Nicola; Massimo Di Giannantonio Journal: Biomed Res Int Date: 2014-05-18 Impact factor: 3.411
Authors: Samuel Carbunaru; Robert S Eisinger; Adolfo Ramirez-Zamora; Dana Bassan; Amin Cervantes-Arriaga; Mayela Rodriguez-Violante; Daniel Martinez-Ramirez Journal: Brain Behav Date: 2018-02-10 Impact factor: 2.708